DTP3 acts as a powerful, selective inhibitor of GADD45β/MKK7. It is designed to engage a critical, cancer-specific survival mechanism that operates downstream from the NF-κB signaling pathway[1]. Administering DTP3 at a concentration of 10 μM for a duration ranging from 1 to 21 days leads to a robust and selective triggering of JNK activation and cell death via apoptosis. This is evidenced by the detection of phosphorylated JNK within 24 hours of treatment[2].
DTP3 动物研究
Animal study
DTP3, when administered subcutaneously at a dose of 14.5 mg/kg/day for 28 days, has been observed to significantly reduce tumor size and effectively eliminate established subcutaneous myeloma xenografts in mice. Additionally, DTP3 administered via intravenous injection at 10 mg/kg/day exhibits a half-life (t1/2) of 1.26 hours, a clearance rate (CL) of 27.13 mL/min/kg, and a volume of distribution (Vd) of 2.80 L/kg[2].
搜索
